{"meta":{"totalResults":9,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"cyclophosphamide-Adriamycin-fluorouracil regimen"},{"type":"Synonym","name":"CAFFI"},{"type":"Synonym","name":"CDF"},{"type":"Abbreviation","name":"CTX/DOX/5-FU"},{"type":"Synonym","name":"cyclophosphamide/doxorubicin/fluorouracil"},{"type":"Synonym","name":"FAC"},{"type":"Synonym","name":"CAF"},{"type":"Synonym","name":"oral CTX/DOX/5-FU"},{"type":"Synonym","name":"oral cyclophosphamide-Adriamycin-fluorouracil regimen"},{"type":"Synonym","name":"oral cyclophosphamide/doxorubicin/fluorouracil"}],"definition":{"html":"A regimen consisting of oral cyclophosphamide, doxorubicin and fluorouracil, used as a treatment for recurrent and metastatic breast cancer.","text":"A regimen consisting of oral cyclophosphamide, doxorubicin and fluorouracil, used as a treatment for recurrent and metastatic breast cancer."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/CAF","text":"CAF"},"nciConceptId":"C9533","nciConceptName":"CAF Regimen","termId":40973,"name":"CAF regimen","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"caf-regimen"},{"aliases":[{"type":"Synonym","name":"cyclophosphamide-methotrexate-fluorouracil regimen"},{"type":"Abbreviation","name":"CMF"},{"type":"CodeName","name":"cyclophosphamide/fluorouracil/methotrexate"},{"type":"Abbreviation","name":"CTX/5-FU/MTX"},{"type":"Synonym","name":"cytoxan-methotrexate-fluorouracil regimen"},{"type":"Synonym","name":"oral cyclophosphamide/methotrexate/fluorouracil"}],"definition":{"html":"A regimen consisting of cyclophosphamide, methotrexate and fluorouracil, used as a neoadjuvant or adjuvant treatment for breast cancer; also used for the treatment of recurrent and metastatic breast cancer.","text":"A regimen consisting of cyclophosphamide, methotrexate and fluorouracil, used as a neoadjuvant or adjuvant treatment for breast cancer; also used for the treatment of recurrent and metastatic breast cancer."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/CMF","text":"CMF"},"nciConceptId":"C9874","nciConceptName":"CMF Regimen","termId":39060,"name":"CMF regimen","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"cmf-regimen"},{"aliases":[{"type":"Synonym","name":"cyclophosphamide/vincristine sulfate (Oncovin)/prednisone/dacarbazine"},{"type":"Synonym","name":"cyclophosphamide/vincristine/prednisone/dacarbazine regimen"},{"type":"Synonym","name":"cyclophosphamide/Oncovin/prednisone/dacarbazine regimen"},{"type":"Abbreviation","name":"COPDAC"},{"type":"Synonym","name":"cyclophosphamide/vincristine sulfate/prednisone/dacarbazine"}],"definition":{"html":"A chemotherapy regimen consisting of cyclophosphamide, vincristine sulfate, prednisone and dacarbazine used for the treatment of male children with classical Hodgkin lymphoma (HL).","text":"A chemotherapy regimen consisting of cyclophosphamide, vincristine sulfate, prednisone and dacarbazine used for the treatment of male children with classical Hodgkin lymphoma (HL)."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/COPDAC","text":"COPDAC"},"nciConceptId":"C123278","nciConceptName":"COPDAC Regimen","termId":774801,"name":"COPDAC regimen","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"copdac-regimen"},{"aliases":[{"type":"Synonym","name":"cyclophosphamide-Oncovin-procarbazine-prednisone regimen"},{"type":"Synonym","name":"cyclophosphamide/prednisone/procarbazine/vincristine"},{"type":"Acronym","name":"COPP"},{"type":"Abbreviation","name":"CTX/PCB/PRED/VCR"},{"type":"Synonym","name":"Cytoxan-Oncovin-procarbazine-prednisone regimen"}],"definition":{"html":"A regimen that is a derivative of the original MOPP regimen consisting of cyclophosphamide, vincristine, procarbazine and prednisone used as an initial treatment for Hodgkin lymphoma. Also used for the treatment of non-Hodgkin lymphoma.","text":"A regimen that is a derivative of the original MOPP regimen consisting of cyclophosphamide, vincristine, procarbazine and prednisone used as an initial treatment for Hodgkin lymphoma. Also used for the treatment of non-Hodgkin lymphoma."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/COPP","text":"COPP"},"nciConceptId":"C9567","nciConceptName":"COPP Regimen","termId":656998,"name":"COPP regimen","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"copp-regimen"},{"aliases":[{"type":"Synonym","name":"cyclophosphamide-vincristine-prednisone regimen"},{"type":"Abbreviation","name":"CVP"},{"type":"Abbreviation","name":"CTX/PRED/VCR"},{"type":"Synonym","name":"cyclophosphamide/prednisone/vincristine"},{"type":"Abbreviation","name":"VCP"},{"type":"Synonym","name":"COP Regimen"}],"definition":{"html":"A regimen consisting of cyclophosphamide, vincristine and prednisone that may be used to treat Castleman disease, post-transplant lymphoproliferative disorders, indolent forms of non-Hodgkin lymphoma and chronic lymphocytic leukemia.","text":"A regimen consisting of cyclophosphamide, vincristine and prednisone that may be used to treat Castleman disease, post-transplant lymphoproliferative disorders, indolent forms of non-Hodgkin lymphoma and chronic lymphocytic leukemia."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/CVP","text":"CVP"},"nciConceptId":"C9573","nciConceptName":"CVP Regimen","termId":657030,"name":"CVP Regimen","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"cvp-regimen"},{"aliases":[{"type":"Abbreviation","name":"CTX"},{"type":"ObsoleteName","name":"Cytoxan"},{"type":"Synonym","name":"cyclophosphamide monohydrate"},{"type":"Synonym","name":"neosar"},{"type":"CodeName","name":"WR- 138719"},{"type":"ForeignBrandName","name":"Genoxal"},{"type":"Synonym","name":"Genoxal"},{"type":"ForeignBrandName","name":"Genuxal"},{"type":"CodeName","name":"Asta B 518"},{"type":"ChemicalStructureName","name":"1-bis(2-chloroethyl)-amino-1-oxo-2-aza-5-oxaphosphoridin monohydrate"},{"type":"ChemicalStructureName","name":"2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate"},{"type":"ChemicalStructureName","name":"2-[bis(b-chloroethyl)amino]-1-oxa-3-aza-2-phosphacyclohexane-2-oxide monohydrate"},{"type":"ChemicalStructureName","name":"2-[di(chloroethyl)amino]-1-oxa-3-aza-2-phosphacyclohexane 2-oxide monohydrate"},{"type":"CodeName","name":"B-518"},{"type":"ChemicalStructureName","name":"bis(2-chloroethyl)phosphoramide cyclic propanolamide ester monohydrate"},{"type":"Synonym","name":"CP monohydrate"},{"type":"ForeignBrandName","name":"CYCLO-cell"},{"type":"ForeignBrandName","name":"Carloxan"},{"type":"Synonym","name":"Ciclofosfamida"},{"type":"Synonym","name":"ciclofosfamide"},{"type":"ForeignBrandName","name":"Cicloxal"},{"type":"ObsoleteName","name":"Clafen"},{"type":"Synonym","name":"Claphene"},{"type":"ForeignBrandName","name":"Cycloblastin"},{"type":"ForeignBrandName","name":"Cycloblastine"},{"type":"Synonym","name":"cyclophospham"},{"type":"Synonym","name":"cyclophosphamid monohydrate"},{"type":"Synonym","name":"cyclophosphamidum"},{"type":"Synonym","name":"cyclophosphan"},{"type":"Synonym","name":"cyclophosphanum"},{"type":"ForeignBrandName","name":"Cyclostin"},{"type":"ForeignBrandName","name":"Cyclostine"},{"type":"ForeignBrandName","name":"Cytophosphan"},{"type":"Synonym","name":"Cytophosphane"},{"type":"ForeignBrandName","name":"Fosfaseron"},{"type":"ForeignBrandName","name":"Ledoxina"},{"type":"Synonym","name":"Mitoxan"},{"type":"ChemicalStructureName","name":"N,N-bis(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide monohydrate"},{"type":"ChemicalStructureName","name":"N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)phosphorodiamidic acid intramolecular ester monohydrate"},{"type":"ChemicalStructureName","name":"N,N-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide monohydrate"},{"type":"ChemicalStructureName","name":"N,N-bis(b-chloroethyl)-N',O-trimethylenephosphoric acid ester diamide monohydrate"},{"type":"ChemicalStructureName","name":"N,N-bis(beta-chloroethyl)-N',O-propylenephosphoric acid ester diamide monohydrate"},{"type":"ChemicalStructureName","name":"N,N-bis(beta-chloroethyl)-N',O-trimethylenephosphoric acid ester diamide monohydrate"},{"type":"Synonym","name":"Syklofosfamid"},{"type":"CodeName","name":"WR-138719"},{"type":"ChemicalStructureName","name":"bis(2-chloroethyl)phosphamide cyclic propanolamide ester monohydrate"},{"type":"CASRegistryName","name":"6055-19-2"},{"type":"ObsoleteName","name":"Revimmune"}],"definition":{"html":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","text":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/cyclophosphamide","text":"Cyclophosphamide"},"nciConceptId":"C405","nciConceptName":"Cyclophosphamide","termId":39748,"name":"cyclophosphamide","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"cyclophosphamide"},{"aliases":[{"type":"Synonym","name":"CHOP-rituximab"},{"type":"Synonym","name":"rituximab-cyclophosphamide-hydroxydaunorubicin-Oncovin-prednisone regimen"},{"type":"Synonym","name":"R-CHOP"},{"type":"Abbreviation","name":"CTX/DOX/MOAB IDEC-C2B8/PRED/VCR"},{"type":"Synonym","name":"cyclophosphamide/doxorubicin/prednisone/rituximab/vincristine"},{"type":"Synonym","name":"Rituxan/CHOP"},{"type":"Synonym","name":"rituximab/cyclophosphamide/doxorubicin/prednisone/vincristine"}],"definition":{"html":"A regimen consisting of cyclophosphamide, doxorubicin, prednisone, rituximab and vincristine that may be used for the treatment of AIDS-related B-cell lymphomas, Castleman disease, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, gastric and nongastric MALT lymphomas, nodular lymphocyte-predominant Hodgkin lymphoma, mantle cell Lymphoma, nodal marginal zone lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), Waldenström macroglobulinemia and lymphoplasmacytic lymphoma, and post-transplant lymphoproliferative disorders.","text":"A regimen consisting of cyclophosphamide, doxorubicin, prednisone, rituximab and vincristine that may be used for the treatment of AIDS-related B-cell lymphomas, Castleman disease, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, gastric and nongastric MALT lymphomas, nodular lymphocyte-predominant Hodgkin lymphoma, mantle cell Lymphoma, nodal marginal zone lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), Waldenström macroglobulinemia and lymphoplasmacytic lymphoma, and post-transplant lymphoproliferative disorders."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/R-CHOP","text":"R-CHOP"},"nciConceptId":"C9760","nciConceptName":"R-CHOP Regimen","termId":632130,"name":"R-CHOP regimen","firstLetter":"r","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"r-chop-regimen"},{"aliases":[{"type":"Synonym","name":"rituximab-cyclophosphamide-vincristine-prednisone regimen"},{"type":"Synonym","name":"CVP-rituximab"},{"type":"Synonym","name":"CVP/rituximab"},{"type":"Synonym","name":"cyclophosphamide/prednisone/rituximab/vincristine"},{"type":"Synonym","name":"cyclophosphamide/vincristine/prednisone/rituximab"}],"definition":{"html":"A regimen consisting of cyclophosphamide, vincristine, prednisone (CVP) and rituximab that may be used in the treatment of some forms of non-Hodgkin's lymphoma (NHL), including follicular lymphoma, gastric and nongastric MALT lymphomas, nodal marginal zone lymphoma (NMZL) and splenic marginal zone lymphoma (SMZL), Castleman disease and post-transplant lymphoproliferative disorders.","text":"A regimen consisting of cyclophosphamide, vincristine, prednisone (CVP) and rituximab that may be used in the treatment of some forms of non-Hodgkin's lymphoma (NHL), including follicular lymphoma, gastric and nongastric MALT lymphomas, nodal marginal zone lymphoma (NMZL) and splenic marginal zone lymphoma (SMZL), Castleman disease and post-transplant lymphoproliferative disorders."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/R-CVP","text":"R-CVP"},"nciConceptId":"C63473","nciConceptName":"R-CVP Regimen","termId":710967,"name":"R-CVP regimen","firstLetter":"r","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"r-cvp-regimen"},{"aliases":[{"type":"Synonym","name":"vincristine/actinomycin-D/cyclophosphamide"},{"type":"Synonym","name":"vincristine/dactinomycin/cyclophosphamide"},{"type":"Synonym","name":"cyclophosphamide/dactinomycin/vincristine"},{"type":"Abbreviation","name":"VAC"}],"definition":{"html":"A regimen consisting of vincristine, dactinomycin and cyclophosphamide that may be used for the treatment of Ewing sarcoma, mesenchymal chondrosarcoma, rhabdomyosarcoma (RMS), malignant sex cord-stromal tumors and malignant germ cell tumors.","text":"A regimen consisting of vincristine, dactinomycin and cyclophosphamide that may be used for the treatment of Ewing sarcoma, mesenchymal chondrosarcoma, rhabdomyosarcoma (RMS), malignant sex cord-stromal tumors and malignant germ cell tumors."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/VAC","text":"VAC"},"nciConceptId":"C67299","nciConceptName":"VAC Regimen","termId":39615,"name":"VAC regimen","firstLetter":"v","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"vac-regimen"}],"links":null}